多发性骨髓瘤(MM)是浆细胞恶性克隆性疾病。上世纪80年代以前,由于药物和治疗手段的限制,治疗以传统烷化剂和糖皮质激素为主,治疗目的为控制和缓解病情,绝大多数患者中位生存时间仅为2.5～3 a。近年来,由于硼替佐米、沙利度胺、雷利度胺等新药的出现及自体造血干细胞移植技术的 Multiple myeloma (MM) is a plasma cell malignant clonal disease. Before the 1980s, due to drug and treatment limitations, the treatment of traditional alkylating agents and glucocorticoid-based treatment for the purpose of control and alleviate the condition, the vast majority of patients with a median survival time of only 2.5 to 3 years. In recent years, due to the emergence of new drugs such as bortezomib, thalidomide, lenalidomide and autologous hematopoietic stem cell transplantation